These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 18814886

  • 21. Are sleep studies helpful in children with Prader-Willi syndrome prior to commencement of growth hormone therapy?
    Vandeleur M, Davey MJ, Nixon GM.
    J Paediatr Child Health; 2013 Mar; 49(3):238-41. PubMed ID: 23438058
    [Abstract] [Full Text] [Related]

  • 22. Sleep cycling alternating pattern (CAP) expression is associated with hypersomnia and GH secretory pattern in Prader-Willi syndrome.
    Priano L, Grugni G, Miscio G, Guastamacchia G, Toffolet L, Sartorio A, Mauro A.
    Sleep Med; 2006 Dec; 7(8):627-33. PubMed ID: 17023209
    [Abstract] [Full Text] [Related]

  • 23. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
    Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Frystyk J, Christiansen JS, Höybye C.
    Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
    [Abstract] [Full Text] [Related]

  • 24. Adenotonsillectomy for obstructive sleep apnea in children with Prader-Willi syndrome.
    Pavone M, Paglietti MG, Petrone A, Crinò A, De Vincentiis GC, Cutrera R.
    Pediatr Pulmonol; 2006 Jan; 41(1):74-9. PubMed ID: 16283627
    [Abstract] [Full Text] [Related]

  • 25. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial.
    Willemsen RH, Arends NJ, Bakker-van Waarde WM, Jansen M, van Mil EG, Mulder J, Odink RJ, Reeser M, Rongen-Westerlaken C, Stokvis-Brantsma WH, Waelkens JJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):485-92. PubMed ID: 17561977
    [Abstract] [Full Text] [Related]

  • 26. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
    Bosio L, Beccaria L, Benzi F, Sanzari A, Chiumello G.
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
    [Abstract] [Full Text] [Related]

  • 27. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study.
    Carrel AL, Myers SE, Whitman BY, Allen DB.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1581-5. PubMed ID: 11932286
    [Abstract] [Full Text] [Related]

  • 28. The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood.
    Butler JV, Whittington JE, Holland AJ, McAllister CJ, Goldstone AP.
    Dev Med Child Neurol; 2010 Jun; 52(6):e88-93. PubMed ID: 20041936
    [Abstract] [Full Text] [Related]

  • 29. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome.
    Miller J, Silverstein J, Shuster J, Driscoll DJ, Wagner M.
    J Clin Endocrinol Metab; 2006 Feb; 91(2):413-7. PubMed ID: 16317059
    [Abstract] [Full Text] [Related]

  • 30. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
    Allen DB, Carrel AL.
    J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
    [Abstract] [Full Text] [Related]

  • 31. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome.
    Meinhardt U, Christiansen JS, Farholt S, Lämmer C, Ostergaard JR, Schmidt F, Kappelgaard AM, Eiholzer U.
    Horm Metab Res; 2013 Jul; 45(7):532-6. PubMed ID: 23632904
    [Abstract] [Full Text] [Related]

  • 32. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database.
    Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-Hübner C, Hokken-Koelega AC, KIGS Steering Committee.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1702-1711. PubMed ID: 28323917
    [Abstract] [Full Text] [Related]

  • 33. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects.
    Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, Bocca G, Haring DA, Hoorweg-Nijman JJ, Houdijk EC, Jira PE, Lunshof L, Odink RJ, Oostdijk W, Rotteveel J, Schroor EJ, Van Alfen AA, Van Leeuwen M, Van Pinxteren-Nagler E, Van Wieringen H, Vreuls RC, Zwaveling-Soonawala N, de Ridder MA, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2013 Oct 01; 98(10):4013-22. PubMed ID: 24001750
    [Abstract] [Full Text] [Related]

  • 34. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Duivenvoorden HJ, Otten BJ, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Apr 01; 94(4):1274-80. PubMed ID: 19158197
    [Abstract] [Full Text] [Related]

  • 35. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
    Grugni G, Marzullo P, Ragusa L, Sartorio A, Trifirò G, Liuzzi A, Crinò A, Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology.
    Clin Endocrinol (Oxf); 2006 Oct 01; 65(4):492-9. PubMed ID: 16984242
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF, Siemensma EP, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, Bocca G, Houdijk EC, Hoorweg-Nijman JJ, Vreuls RC, Jira PE, van Trotsenburg AS, Bakker B, Schroor EJ, Pilon JW, Wit JM, Drop SL, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Nov 01; 94(11):4205-15. PubMed ID: 19837938
    [Abstract] [Full Text] [Related]

  • 37. Body composition in Prader-Willi syndrome compared with nonsyndromal obesity: Relationship to physical activity and growth hormone function.
    van Mil EG, Westerterp KR, Gerver WJ, Van Marken Lichtenbelt WD, Kester AD, Saris WH.
    J Pediatr; 2001 Nov 01; 139(5):708-14. PubMed ID: 11713451
    [Abstract] [Full Text] [Related]

  • 38. Prader-Willi syndrome: who can have growth hormone?
    Stafler P, Wallis C.
    Arch Dis Child; 2008 Apr 01; 93(4):341-5. PubMed ID: 18089632
    [Abstract] [Full Text] [Related]

  • 39. Sudden death in Prader-Willi syndrome during growth hormone therapy.
    Sacco M, Di Giorgio G.
    Horm Res; 2005 Apr 01; 63(1):29-32. PubMed ID: 15583479
    [Abstract] [Full Text] [Related]

  • 40. Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome.
    Obata K, Sakazume S, Yoshino A, Murakami N, Sakuta R.
    J Pediatr Endocrinol Metab; 2003 Feb 01; 16(2):155-62. PubMed ID: 12713251
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.